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Research Curcumin inhibits cholesterol uptake in Caco-2 
cells by down-regulation of NPC1L1 expression
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Abstract
Background: Curcumin is a polyphenol and the one of the principle curcuminoids of the spice turmeric. Its 
antioxidant, anti-cancer and anti-inflammatory effects have been intensively studied. Previous in vivo studies showed 
that administration of curcumin also decreased cholesterol levels in the blood, and the effects were considered to be 
related to upregulation of LDL receptor. However, since plasma cholesterol levels are also influenced by the uptake of 
cholesterol in the gut, which is mediated by a specific transporter Niemann-Pick Cl-like 1 (NPC1L1) protein, the present 
study is to investigate whether curcumin affects cholesterol uptake in the intestinal Caco-2 cells.
Methods: Caco-2 cells were cultured to confluence. The micelles composed of bile salt, monoolein, and 14C-
cholesterol were prepared. We first incubated the cells with the micelles in the presence and absence of ezetimibe, the 
specific inhibitor of NPC1L1, to see whether the uptake of the cholesterol in the cells was mediated by NPC1L1. We 
then pretreated the cells with curcumin at different concentrations for 24 h followed by examination of the changes of 
cholesterol uptake in these curcumin-treated cells. Finally we determined whether curcumin affects the expression of 
NPC1L1 by both Western blot analysis and qPCR quantification.
Results: We found that the uptake of radioactive cholesterol in Caco-2 cells was inhibited by ezetimibe in a dose-
dependent manner. The results indicate that the uptake of cholesterol in this study was mediated by NPC1L1. We then 
pretreated the cells with 25-100 μM curcumin for 24 h and found that such a treatment dose-dependently inhibited 
cholesterol uptake with 40% inhibition obtained by 100 μM curcumin. In addition, we found that the curcumin-
induced inhibition of cholesterol uptake was associated with significant decrease in the levels of NPC1L1 protein and 
NPC1L1 mRNA, as analyzed by Western blot and qPCR, respectively.
Conclusion: Curcumin inhibits cholesterol uptake through suppression of NPC1L1 expression in the intestinal cells.
Introduction
Elevated plasma cholesterol levels constitute a major risk
factor for atherosclerosis and coronary heart diseases [1].
The levels of plasma cholesterol are influenced by de
novo biosynthesis, absorption in the gut, and the removal
of cholesterol from the blood [2]. The intestine plays a
major role in regulating cholesterol homeostasis and
about 36% reductions of plasma cholesterol could be
achieved by total inhibition of cholesterol absorption [3].
Absorption of cholesterol is a multi-step process in which
cholesterol is micellized by bile acids in the intestinal
lumen, taken up by the enterocytes, assembled into lipo-
proteins, and transported to the lymph and the circula-
tion. Niemann-Pick C1-like 1(NPC1L1) protein has been
identified as a specific transporter for cholesterol uptake
at the surface of plasma membrane [4]. Ezetimibe is a
well-known inhibitor of NPC1L1 and has been widely
used as an effective cholesterol-lowering drug for treating
patients with hypercholesterolemia[5].
Curcumin is the major constituent of turmeric curcum-
inoids and has been found to have antioxidant, anti-
tumor, anti-inflammatory properties [6-8]. Besides these
well-known effects, curcumin was also found to affect
lipid metabolism. More than 30 years ago, Rao et al
showed that administration of curcumin decreased cho-
lesterol levels in the blood and liver in normal animals [9].
Similar reductions were also identified thereafter in dia-
betic animals and animals fed high fat [10-12] and in
healthy humans, varied with the dose, age and the period
of administration [13-15]. The mechanism underlying the
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hypocholesterolemic effect may be related to the upregu-
lation of LDL receptor [16,17]. Since plasma cholesterol
levels are also influenced by absorption of cholesterol in
the gut, we, in the present study, addressed a question
whether curcumin affects the cholesterol uptake in the
enterocytes.
Materials and methods
Materials
Caco-2 cells were obtained from American Tissue Cul-
ture Collection. The Modified Eagle Medium (DMEM),
M199 medium, heat-inactivated fetal bovine serum
(FBS), 1% non-essential amino acids were purchased
from either Invitrogen or Sigma-Aldrich (Stockholm,
Sweden). [14C] cholesterol (50 mCi/mmol) was purchased
from American Radiolabeled Chemicals Inc (St. Louis,
MO, USA). Curcumin (purity > 98%) was purchased from
Sigma-Aldrich. NPC1L1 antibody was purchased from
Santa Cruz (Santa Cruz, USA). QT-PCR kit was obtained
from Bio-Rad (Stockholm, Sweden). Primers used in
quantification of mRNA of NPC1L1 by qPCR were syn-
thesized from DNA Technology (Rysskov, Denmark).
Ezetimibe (purity >95%) was kindly provided by Scher-
ing-Plough Research Institute (Kenilworth, USA).
Preparation of delipidized fetal bovine serum and 
cholesterol micellar solutions
The preparation of delipidized FBS was according to Gib-
son et al [18]. In brief, 20 g thixotropic gel powder (Cab-
o-sil, Kodak) was added to 1 liter FBS and stirred over-
night at 4°C. The mixture was then centrifuged at 15,000
rpm at 4°C for 1 h and the supernatant was collected and
sequentially filtered through 0.20 μm filter. For preparing
micellar cholesterol solutions, M199 culture media con-
taining 3 mM sodium taurocholate, 30 μM monoolein
and 1 nM [14C]cholesterol (1.25 × 1 05 dpm) were mixed
and sonicated, as reported by Field et al [19]. The micellar
solution was then passed through a 0.20 μm filter and
kept at 37°C until use.
Cell culture and stimulation
Caco-2 cells were cultured in 6 well plate in DMEM, con-
taining 10% FBS, 1% penicillin-streptomycin, 2 mM L-
glutamate, 1% non-essential-amino acids to confluence as
described by Eckhardt et al [20]. Prior to experiment, the
c u l t u r e  m e d i u m  w i t h  1 0 %  F B S  w a s  r e p l a c e d  w i t h  t h e
medium containing the delipidized FBS, followed by
incubating the cells for 24 h. The cells were then washed
three times with M199 buffer, and then incubated with
fresh medium containing the cholesterol micelles for 2 h.
The medium was then removed and the cells were
washed three times with ice-cold PBS. After centrifuga-
tion, the cell pellets were dissolved in 0.5 ml of 0.1 M
NaOH and an aliquot of 0.1 ml of the lysate was taken for
liquid scintillation counting. The protein concentration
of the lysate was quantified by a kit from Bio-Rad and the
results of incorporated cholesterol into Caco-2 cells were
expressed as dpm/mg protein. To confirm that the uptake
of cholesterol under this experimental conditions was
mediated by NPC1L1 not passive diffusion, some cells
were pretreated with ezetimibe, the inhibitor of NPC1L1,
for 2 h. The changes of cholesterol uptake induced by
ezetimibe were examined.
To study the effects of curcumin on cholesterol uptake,
curcumin was freshly dissolved in dimethyl sulfoxide
(DMSO) at different concentrations and immediately
diluted in the DMEM culture medium as described
above. The cells were pretreated with curcumin with dif-
ferent concentrations for 24 h. The final concentration of
DMSO in the medium was 0.1% and the control cells
were incubated with 0.1% DMSO only. After the pretreat-
ment, the medium was removed and the cells were
washed three times with ice-cold PBS, followed by incu-
bation with the cholesterol micelles as described above.
The cholesterol uptakes in the cells with and without cur-
cumin treatment were compared.
RNA estimation by real time quantitative RT-PCR(QT-PCR)
RNA was extracted from the cells using TRIzol reagents
and converted to cDNA by a kit from Fermentas (Hels-
ingborg, Sweden). The primers used in qPCR to quantify
the mRNA of NPC1L1 were shown in Table 1. The cDNA
isolated from the cells was mixed with the appropriate
primers and 2 × SYBR Green PCR master mix (Bio-Rad)
in 20 μl. Real-time RT-PCR was performed using the Bio-
Rad iCycler system. The thermal cycler program was as
follows: holding for 3 min at 95°C for one cycle, followed
by amplification of cDNA for 45 cycles with melting for
15 s at 95°C, and annealing and extension for 1 min at
60°C. The mass of PCR products generated was estimated
after each PCR cycle, and threshold cycle number is
determined in the exponential phase of the curve. The
values were normalized using GAPDH as an endogenous
internal standard. The relative expression of the gene was
Table 1: Primers used in this study.
Primer Sequence
Human NPC1L1-F 5'-TATGGTCGCCCGAAGCA-3'
Human NPC1L1-R 5'-
TGCGGTTGTTCTGGAAATACT
G-3'
GAPDH-F 5'-
CATGAGAAGTATGACAACAG
CCT-3'
GAPDH-R 5'-
AGTCCTTCCACGATACCAAA
GT-3'Feng et al. Lipids in Health and Disease 2010, 9:40
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calculated using the comparative threshold cycle (Ct)
method.
Western blot
The cells were lysed and the cell free extract was prepared
as described [21]. Proteins (40 μg) in cell lysate were sub-
jected to 7.5% SDS PAGE. The resolved proteins in the gel
were transferred to a nitrocellulose membrane electro-
phoretically overnight. The membranes were incubated
with anti-NPC1L1 antibody (1:5000) and then with sec-
ond antibody (1:50000) conjugated with horseradish per-
oxidase. The specific NPC1L1 bands (145 kD) were
identified by enhanced chemiluminescence advance
reagent. The membranes were then stripped and re-
probed with anti-actin antibody as a loading control.
Statistical analysis
The results are presented as mean ± S.E.M. Statistical
analyses were performed using one-way analysis of vari-
ance (ANOVA) followed by the Bonferroni posttest for
multiple comparisons. Differences were considered sig-
nificant at P < 0.05.
Results
Uptake of cholesterol in Caco-2 cells was inhibited by 
ezetimibe
Because uptake of cholesterol in the intestinal tract was
mediated by NPC1L1 whose functions can be inhibited
specifically by ezetimibe [4,5], we first examined whether
cholesterol uptake in Caco-2 cells under the experimental
conditions was related to the functions of NPC1L1. The
answer is positive. As shown in Fig. 1, the cholesterol
uptake was dose dependently inhibited by ezetimibe.
Curcumin inhibited cholesterol uptake in Caco-2 cells
We then addressed a question whether curcumin can
inhibit cholesterol uptake. After pretreating the cells with
curcumin for 24 h, we found that cholesterol uptake in
Caco-2 cells was decreased with the increasing concen-
trations of curcumin (Fig. 2). The threshold concentra-
tion of curcumin is about 25 μM and at 100 μM curcumin
decreased cholesterol uptake by about 40%.
The effects of curcumin were associated with decreased 
NPC1L1 protein expression
We then further studied whether curcumin could influ-
ence the levels of NPC1L1 in the intestinal cells. As
shown in upper panel of Fig. 3, pretreatment of the cells
with different concentrations of curcumin for 24 h signif-
icantly attenuated NPC1L1 protein levels. No similar
changes could be identified for the levels of actin. To dis-
tinguish whether the effect was caused by an increased
degradation or a decreased biosynthesis, the levels of
mRNA of NPC1L1 after treating the cells with curcumin
were quantified. As shown in the lower panel of Fig. 3,
curcumin induced a dose-dependent reduction of
NPC1L1 mRNA, as normalized with that of control gene
GAPDH. About 50% inhibition could be identified by 50
μM curcumin.
Discussion
Previous studies in animals and humans have shown that
administration of curcumin decreased the cholesterol
levels in blood (11-14). The mechanism underlying the
effects was considered to be related to the increased
Figure 2 Inhibitory effect of curcumin on micellar cholesterol ab-
sorption in Caco-2 cells. The cells were pretreated with curcumin at 
different concentrations for 24 h, then incubated with radioactive mi-
cellar cholesterol for 2 h. The uptake of cholesterol in the absence of 
curcumin was normalized to 100%. Results are mean ± SEM from trip-
licate determinations in three separate experiments.
Figure 1 Cholesterol uptake by Caco-2 cells is mediated by 
NPC1L1. The cells were cultured to 100% confluence and pretreated 
with ezetimibe at different concentrations for 2 h. The cells were then 
incubated with radioactive micellar cholesterol for 2 h. The cells were 
then lysed and the uptake of radioactive cholesterol was quantified by 
liquid scintillation. Results are mean ± SEM of duplicate determinations 
in three separate experiments. * P < 0.05, ** P < 0.01.Feng et al. Lipids in Health and Disease 2010, 9:40
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expression of LDL receptor [16,17]. Since intestinal
absorption of cholesterol also affects the levels of choles-
terol in the blood, whether uptake of cholesterol in the
enterocytes can be affected by curcumin is therefore an
important question to be studied. Our results for the first
time show that curcumin has inhibitory effects on choles-
terol uptake and the inhibition is mediated by down-reg-
ulation of NPC1L1 expression. The conclusion is
supported by the evidence from 3 lines in the present
study. First, the uptake of cholesterol into Caco-2 cells
was a process mediated by NPC1L1, since it could be
inhibited in a dose-dependent manner by ezetimibe, a
specific inhibitor of NPC1L1. Second, the NPC1L1 pro-
tein in the cells was decreased by treating the cells with
curcumin. And third, the reduced NPC1L1 protein was
most likely resulted from a decreased expression, as a sig-
nificant decrease of NPC1L1 mRNA was demonstrated
by curcumin treatment in a dose dependent manner.
Curcumin is one of the most intensively studied plant
components and most of the studies are focused on its
antiinflammatory and anticancer effects [22-24]. How-
ever, its hypocholesterolemic effects have documented
for more than 30 years [9-15]. Most of the previous stud-
ies were performed in animal models followed by analysis
of the cholesterol levels in the blood and liver. The most
consistent finding from the previous studies is a
decreased cholesterol level in the blood. The mechanism
for such a decrease was suggested to be mediated by an
upregulation of LDL receptor [16,17]. The present work
demonstrated a novel effect of the component in the gut,
i.e. to inhibit the expression of NPC1L1 in the entero-
cytes. Our results indicate that curcumin can decrease
the cholesterol levels by two mechanisms, one in the
intestine to inhibit the uptake via NPC1L1 transporter,
and the other in the blood to increase the clearance by
LDL receptor. Considering the poor absorption in the gut
and low concentration of curcumin in the blood [24], its
effect in the intestinal tract might be of more physiologi-
cal implications than its systemic effects.
NPC1L1 is a crucial transporter for cholesterol uptake.
Understanding the regulation of its expression is of
importance in human health and disease. It is only
recently that several studies showed that diet with low
cholesterol and low fat increased the NPC1L1 expression
in the small intestine in hamster [25]. A few dietary fac-
tors such as phytosterol [26], PUFA [27] and dietary sup-
plement probiotics [28] may also affect expression of
NPC1L1. Although the molecular signals regulating the
expression of NPC1L1 is not clear, several nuclear recep-
tors such as sterol responsive element binding protein
2 ( S R E B P 2 ) ,  L X R  a n d  H N F 4 α  m i g h t  b e  i n v o l v e d  [ 2 9 ] .
Overexpression of SREBP2 results in an enhanced tran-
scription of NPC1L1. Curcumin has been shown to affect
the functions of about 50 transcriptional factors [22,30].
Whether some of these factors are linked to the nuclear
receptor, leading to the inhibition of the expression of
NPC1L1 requires further investigation in the future.
Conclusion
Curcumin, the dietary polyphenol isolated from turmeric
can inhibit cholesterol uptake in the enterocytes by inhib-
iting the expression of NPC1L1, the key transporter of
cholesterol in the cell membrane.
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Figure 3 The effect of curcumin on NPC1L1 protein expression in 
Caco-2 cells. In the upper panel, the cells were treated with curcumin 
at different concentrations for 24 h, and the whole-cell lysates were an-
alyzed by Western blot. The results are representative of three inde-
pendent experiments. In the lower panel, NPC1L1 mRNA abundance 
was determined by real-time RT-PCR as described in Methods. Expres-
sion values were normalized to housekeeping genes, and expression 
in untreated cells was set to 1. Values shown represent means ± SEM 
of three independent experiments, * P < 0.01, ** P < 0.001 compared to 
untreated cells.Feng et al. Lipids in Health and Disease 2010, 9:40
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